Cytosorbents (CTSO) Expected to Announce Quarterly Earnings on Monday

Cytosorbents (NASDAQ:CTSO) is projected to announce its earnings results after the market closes on Monday, March 31st. Analysts expect Cytosorbents to post earnings of ($0.07) per share and revenue of $10.09 million for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Cytosorbents Price Performance

Shares of CTSO opened at $0.98 on Monday. The firm has a market capitalization of $53.78 million, a PE ratio of -2.73 and a beta of 0.78. The company’s 50-day moving average is $1.07 and its 200-day moving average is $1.05. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.61. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CTSO. D. Boral Capital reissued a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a research report on Tuesday, February 25th. StockNews.com began coverage on shares of Cytosorbents in a research report on Tuesday, March 18th. They issued a “hold” rating on the stock. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $4.67.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.